A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

• Status: Completed
• Trial end date: 2021-02-20
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Taro Pharmaceuticals USA

Criteria

Inclusion Criteria:

• Healthy male or non pregnant female aged ≥ 18 years

• Subjects must have provided IRB approved written informed consent

• Subjects must have clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).

Exclusion Criteria:

• Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.

• Subjects with a history of hypersensitivity or allergy to any of the study medication ingredients and its excipients.

• Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.